Truist upgraded Pacira (PCRX) to Hold from Sell with a price target of $25, up from $8. Following meetings with management, the firm is “more comfortable” around the defensibility of Exparel’s new patent family and now inclined to make a call that management is more likely to settle with eVenus to “end its litigation woes and move on,” the analyst tells investors. The firm now models generic entry in about 2036, versus previously assuming 2025, the analyst added.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCRX:
- Pacira upgraded to Hold from Sell at Truist
- Pacira Pharmaceuticals Announces Leadership Changes and Plan Amendment
- Pacira appoints Teehan as CCO, Corbett as CBO
- Shareholders that lost money on Pacira BioSciences, Inc.(PCRX) should contact Levi & Korsinsky LLP about pending Class Action – PCRX
- Pacira price target raised to $30 from $22 at Needham